About: Challenges in Drug Development Posed by the COVID‐19 Pandemic: An Opportunity for Clinical Pharmacology

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Challenges in Drug Development Posed by the COVID‐19 Pandemic: An Opportunity for Clinical Pharmacology Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Challenges in Drug Development Posed by the COVID‐19 Pandemic: An Opportunity for Clinical Pharmacology
Creator	Benincosa, Lisa Dong, Jennifer Venkatakrishnan, Karthik Yalkinoglu, Oezkan
Source	Medline; PMC
abstract	The unprecedented challenges posed by the coronavirus disease 2019 (COVID‐19) pandemic highlight the urgency for applying clinical pharmacology and model‐informed drug development in (i) dosage optimization for COVID‐19 therapies, (ii) approaching therapeutic dilemmas in clinical trial settings, and (iii) maximizing value of information from impacted non–COVID‐19 trials. More than ever, we have a responsibility for adaptive evidence synthesis with a Totality of Evidence mindset in this race against time across biomedical research, clinical practice, drug development, and regulation.
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1002/cpt.1879
bibo:pmid	32356569
has license	no-cc
sha1sum (hex)	62d5d2ec98854b0b8a74eef9bee84ef4053f2362
schema:url	https://doi.org/10.1002/cpt.1879
resource representing a document's title	Challenges in Drug Development Posed by the COVID‐19 Pandemic: An Opportunity for Clinical Pharmacology
has PubMed Central identifier	PMC7267567
has PubMed identifier	32356569
schema:publication	Clin Pharmacol Ther
resource representing a document's body	covid:62d5d2ec98854b0b8a74eef9bee84ef4053f2362#body_text
is schema:about of	named entity 'COVID-19' named entity 'clinical trial' named entity 'Opportunity' named entity 'Pandemic' named entity 'time' named entity 'mindset' named entity 'responsibility' named entity 'adaptive' named entity 'More' named entity 'pandemic' named entity 'drug development' named entity 'Challenges' named entity 'COVID-19' named entity 'COVID' named entity 'coronavirus disease 2019' named entity 'COVID' named entity 'clinical trial' named entity 'adjunctive therapy' named entity 'pharmacokinetic' named entity 'coronavirus disease 2019' named entity 'hydroxychloroquine' named entity 'pharmacodynamic' named entity 'World Health Organization' named entity 'anticancer agent' named entity 'sample size' named entity 'rare diseases' named entity 'statistical analyses' named entity 'EMA' named entity 'drug development' named entity 'US Food and Drug Administration' named entity 'type 2' named entity 'statistical power' named entity 'drug development' named entity 'refractory' named entity 'COVID' named entity 'clinical trials' named entity 'preclinical' named entity 'COVID' named entity 'critical care' named entity 'self-medication' named entity 'physiological parameters' named entity 'drug developer' named entity 'stage of development' named entity 'physiologically-based' named entity 'polypharmacy' named entity 'Clinical pharmacologists' named entity 'COVID-19' named entity 'lopinavir/ritonavir' named entity 'angiotensin-converting enzyme' named entity 'electronic health records' named entity 'clinical trials' named entity 'proof-of-concept' named entity 'drug development' named entity 'rheumatoid arthritis' named entity 'pharmacodynamic' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'clinical pharmacologists' named entity 'chloroquine' named entity 'COVID' named entity 'potential treatments' named entity 'clinical studies' named entity 'population pharmacokinetic' named entity 'pharmacokinetic' named entity 'pharmacokinetic' named entity 'risk assessment' named entity 'acute respiratory distress' named entity 'precision medicine' named entity 'pharmacodynamic' named entity 'hydroxychloroquine' named entity 'vital signs' named entity 'rare genetic disease' named entity 'statistical analyses' named entity 'phenotype' named entity 'community of practice' named entity 'INSERM' named entity 'drug development' named entity 'type 1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software